Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it would be presenting four posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2007, in San Francisco, CA.

GERMANTOWN, Md., July 12 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , today announced the initiation of a Phase II clinical trial in pancreatic cancer patients. The protocol has been activated and is now open for enrollment as patients are being evaluated to start study treatment.

GERMANTOWN, Md., June 19 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , today announced continued positive interim results from its Phase I study of AVN944, for the treatment of hematologic malignancies in elderly and refractory patients.

GERMANTOWN, Md., June 13 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , today announced that it is will provide an update on the Phase I clinical trial of AVN944 in hematologic malignancies on Tuesday, June 19, 2007, after the close of the U.S. financial markets.

GERMANTOWN, Md., April 18 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , today described the potent antiproliferative activity of AVN944 in human endothelial cells (HUVEC), and showed that the compound prevents blood vessel formation in a mouse model.